Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis

Pourani, Mohammad Reza; Abdollahimajd, Fahimeh; Zargari, Omid; Dadras, Mohammad Shahidi

doi:10.1080/09546634.2021.1966357

Cited by 22 publications

(18 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, systemic inflammatory processes could cause endothelial dysfunction, increased arterial thickness, vascular inflammation, and insulin resistance, which could lead to CVD in patients with psoriasis 28 – 31 . Early studies of biomarkers for psoriasis focused on underlying pathophysiologic processes and various circulating biomarkers for diagnosis, severity, and treatment response of in patients with psoriasis have been reported 2 , 6 , 8 , 32 . For example, serum levels of inflammatory and pro-inflammatory markers including C-reactive protein (CRP), complement 3 (C3), platelet P-selectin, tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, IL-12, and IL-18 were increased in patients with psoriasis 9 , 10 .…”

Section: Discussionmentioning

confidence: 99%

Quantitative proteomic analysis of human serum using tandem mass tags to predict cardiovascular risks in patients with psoriasis

Kim

Back

Shin

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Although biomarker candidates associated with psoriasis have been suggested, those for predicting the risk of cardiovascular disease (CVD) early in patients with psoriasis are lacking. We aimed to identify candidate biomarkers that can predict the occurrence of CVD in psoriasis patients. We pursued quantitative proteomic analysis of serum samples composed of three groups: psoriasis patients with and those without CVD risk factors, and healthy controls. Age/Sex-matched serum samples were selected and labeled with 16-plex tandem mass tag (TMT) and analyzed using liquid chromatography-mass spectrometry and subsequent verification with ELISA. Of the 184 proteins that showed statistical significance (P-value < 0.05) among the three groups according to TMT-based quantitative analysis, 98 proteins showed significant differences (> 2.0-fold) between the psoriasis groups with and without CVD risk factors. Verification by ELISA revealed that caldesmon (CALD1), myeloid cell nuclear differentiation antigen (MNDA), and zyxin (ZYX) levels were significantly increased in the psoriasis group with CVD risk factors. Further network analysis identified pathways including integrin signaling, which could be related to platelet aggregation, and actin cytoskeleton signaling. Three novel candidates (MNDA, ZYX, and CALD1) could be potential biomarkers for predicting CVD risks in psoriasis patients. We expect these biomarker candidates can be used to predict CVD risk in psoriasis patients in clinical settings although further studies including large validation are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative proteomic analysis of human serum using tandem mass tags to predict cardiovascular risks in patients with psoriasis

Kim

Back

Shin

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The stimulation of the human keratinocyte cell line - HaCaT with ultraviolet B radiation upregulated the production of IL-18 ( 198 ). Several studies have strongly indicated that IL-18 is a strong biomarker for clinical psoriasis symptoms ( 139 , 140 , 199 ). Overall, these data may indicate the potential role of IL-18 in psoriasis therapy.…”

Section: Pathophysiological Autoimmune Conditions Associated With Il-18mentioning

confidence: 99%

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

et al. 2022

View full text Add to dashboard Cite

Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine involved in host defense against infections and regulates the innate and acquired immune response. IL-18 is produced by both hematopoietic and non-hematopoietic cells, including monocytes, macrophages, keratinocytes and mesenchymal cell. IL-18 could potentially induce inflammatory and cytotoxic immune cell activities leading to autoimmunity. Its elevated levels have been reported in the blood of patients with some immune-related diseases, including rheumatoid arthritis, systemic lupus erythematosus, type I diabetes mellitus, atopic dermatitis, psoriasis, and inflammatory bowel disease. In the present review, we aimed to summarize the biological properties of IL-18 and its pathological role in different autoimmune diseases. We also reported some monoclonal antibodies and drugs targeting IL-18. Most of these monoclonal antibodies and drugs have only produced partial effectiveness or complete ineffectiveness in vitro, in vivo and human studies. The ineffectiveness of these drugs targeting IL-18 may be largely due to the loophole caused by the involvement of other cytokines and proteins in the signaling pathway of many inflammatory diseases besides the involvement of IL-18. Combination drug therapies, that focus on IL-18 inhibition, in addition to other cytokines, are highly recommended to be considered as an important area of research that needs to be explored.

show abstract

“…To better diagnose and treat PsO, a wide range of biomarkers and targets have been investigated. [10][11][12] Inflammatory-related mediators such as IL-17A, IL23A, and TNF-α have been reported to be important biomarkers for disease activity of PsO. 2,10 Based on the pathological process of PsO, targeting related signaling pathways and molecules can be an effective way to develop therapeutic drugs.…”

Section: Introductionmentioning

confidence: 99%

“…[10][11][12] Inflammatory-related mediators such as IL-17A, IL23A, and TNF-α have been reported to be important biomarkers for disease activity of PsO. 2,10 Based on the pathological process of PsO, targeting related signaling pathways and molecules can be an effective way to develop therapeutic drugs. In an imiquimod (IMQ)-induced mouse model, Bruton's tyrosine kinase inhibitors significantly reduced psoriatic inflammation.…”

Section: Introductionmentioning

confidence: 99%

Serum LL‐37 and inflammatory cytokines levels in psoriasis

Lao

Xie

Qin

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background: Psoriasis (PsO) is a T-cell-associated inflammatory autoimmune dermatitis. Leucine leucine-37 (LL-37) is upregulated in PsO patients and correlated with the area and severity of PsO. However, the exact relation between LL-37 and T cell-associated inflammation is not well understood. It is very important to clarify the relationship between LL-37 and inflammatory response for clinical diagnosis and treatment of PsO. This study investigated the serum levels of LL-37 and inflammatory cytokines, as well as correlations between them in PsO patients, which aimed to provide new ideas for the diagnosis and treatment of PsO. Methods: PsO patients (n = 50) and healthy volunteers (n = 33) were recruited in this study. Skin specimens were stained with hematoxylin and eosin (H&E). The serum levels of LL-37, T-helper type 1 (Th1, IFN-γ), T-helper type 17 (Th17, IL-17), T-helper type 22 (Th22, IL-22), and T-helper type 2cytokines (Th2, IL-4) were assessed by enzyme-linked immunosorbent assay. Some of the patients were re-recruited after treatment to evaluate LL-37 and cytokines levels.Results: Pathological changes were observed in PsO skin lesions. LL-37, IFN-γ, IL-17, and IL-22 serum levels were much higher in PsO patients than those in healthy volunteers (p < .001), and posttreatment reduction was observed in five patients. However, no remarkable difference in IL-4 level (p > .05) was found. LL-37 level was positively correlated with IFN-γ, IL-17, and IL-22 levels (p < .001) in PsO patients. Conclusion: LL-37 expression was significantly associated with inflammatory response, which may provide us new ideas for diagnosing and monitoring disease activity of PsO.

show abstract

Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis

Cited by 22 publications

References 68 publications

Quantitative proteomic analysis of human serum using tandem mass tags to predict cardiovascular risks in patients with psoriasis

Quantitative proteomic analysis of human serum using tandem mass tags to predict cardiovascular risks in patients with psoriasis

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

Serum LL‐37 and inflammatory cytokines levels in psoriasis

Contact Info

Product

Resources

About